A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors


To assess the safety and tolerability of TTX-080



You may be eligible for this study if you meet the following criteria:

  • Conditions: tumor
  • Age: Between 18 Years - 100 Years
  • Gender: Male or Female
Updated on 20 Nov 2022 . Study ID: TX11413
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center